Assessing Pulmonary Hypertensive Vascular Disease in Childhood

被引:95
|
作者
del Cerro Marin, M. J. [1 ]
Sabate Rotes, A. [2 ]
Rodriguez Ogando, A. [3 ]
Mendoza Soto, A. [4 ]
Quero Jimenez, M. [1 ]
Gavilan Camacho, J. L. [5 ]
Raposo Sonnenfeld, I. [6 ]
Moya Bonora, A. [7 ]
Albert Brotons, D. C. [8 ]
Moreno Galdo, A. [9 ]
机构
[1] Ramon y Cajal Univ Hosp, Dept Pediat Cardiol, Madrid, Spain
[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
[3] Hosp Gregorio Maranon, Dept Pediat Cardiol, Madrid, Spain
[4] Hosp Univ 12 Octubre, Dept Pediat Cardiol, Madrid, Spain
[5] Complejo Hospitalario Virgen Rom, Dept Pediat Cardiol, Seville, Spain
[6] Complejo Hosp Univ Juan Canalejo, Dept Pediat Cardiol, Coruna, Spain
[7] Hosp Infantil Univ La Fe, Dept Pediat Cardiol, Valencia, Spain
[8] Univ Autonoma Barcelona, Hosp Vail dHebron, Dept Pediat Cardiol, E-08193 Barcelona, Spain
[9] Univ Autonoma Barcelona, Hosp Vail dHebron, Pediat Pulmonol Unit, E-08193 Barcelona, Spain
关键词
pulmonary hypertension; pediatrics; registries; epidemiology; survival; ARTERIAL-HYPERTENSION; CLINICAL-FEATURES; BRONCHOPULMONARY DYSPLASIA; HEART DISEASE; CHILDREN; OUTCOMES; SURVIVAL; REGISTRY; INSIGHTS; INFANTS;
D O I
10.1164/rccm.201406-1052OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: There is a lack of knowledge regarding the epidemiology, clinical characterization, and survival in pediatric pulmonary hypertension. Objectives: To describe the epidemiology, outcomes, and risk factors for mortality in pediatric pulmonary hypertension in Spain. Methods: We analyzed data from the Spanish Registry for Pediatric Pulmonary Hypertension. From January 2009 to June 2012, a total of 225 patients diagnosed with pulmonary hypertension in 1998 or after were collected from 21 referral and nonreferral centers. We included all Nice etiologies, estimated incidence and prevalence of pulmonary hypertension in the Spanish pediatric population, and analyzed risk factors for mortality (Nice etiologic group, clinical and hemodynamic variables). Patients were classified as follows: group I, pulmonary arterial hypertension (n = 142; 61%); group II, left heart disease (n = 31; 14%); group III, respiratory disease (n = 41; 18%); group IV, thromboembolic pulmonary hypertension (n = 2; 1%); or group V, mostly inherited metabolic diseases (n = 10; 4.5%). Of the patients studied, 31% had multifactorial pulmonary hypertension. Measurements and Main Results: Mean age at diagnosis was 4.3 +/- 4.9 years (50% < 2 yr). Survival rates at 1 and 3 years were 80 and 74% for the whole cohort, and 89 and 85% for patients with pulmonary arterial hypertension. Independent risk factors for mortality included an etiologic group other than pulmonary arterial hypertension (P < 0.001), age at diagnosis younger than 2 years old (P < 0.001), advanced functional class at diagnosis (P < 0.001), and high right atrial pressure at diagnosis (P = 0.002). Conclusions: In moderate to severe pediatric pulmonary hypertension, the prognosis is better in pulmonary arterial hypertension than in other Nice categories. In pediatric pulmonary hypertension age at diagnosis younger than 2 years is a risk factor for mortality, in addition to the previously established risk factors.
引用
收藏
页码:1421 / 1429
页数:9
相关论文
共 50 条
  • [1] Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease
    Humpl, Tilman
    Reyes, Janette T.
    Erickson, Simon
    Armano, Ruth
    Holtby, Helen
    Adatia, Ian
    CARDIOLOGY IN THE YOUNG, 2011, 21 (02) : 187 - 193
  • [2] Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry
    Abman, Steven H.
    Mullen, Mary P.
    Sleeper, Lynn A.
    Austin, Eric D.
    Rosenzweig, Erika B.
    Kinsella, John P.
    Ivy, Dunbar
    Hopper, Rachel K.
    Raj, J. Usha
    Fineman, Jeffrey
    Keller, Roberta L.
    Bates, Angela
    Krishnan, Usha S.
    Avitabile, Catherine M.
    Davidson, Alexander
    Natter, Marc D.
    Mandl, Kenneth D.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (01)
  • [3] Cardiac Catheterization in Children with Pulmonary Hypertensive Vascular Disease
    Bobhate, Prashant
    Guo, Long
    Jain, Shreepal
    Haugen, Richard
    Coe, James Y.
    Cave, Dominic
    Rutledge, Jennifer
    Adatia, Ian
    PEDIATRIC CARDIOLOGY, 2015, 36 (04) : 873 - 879
  • [4] Improving Outcomes for Pulmonary Vascular Disease
    Robbins, Ivan M.
    Moore, Timothy M.
    Blaisdell, Carol J.
    Abman, Steven H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 185 (09) : 1015 - 1020
  • [5] Prematurity and Pulmonary Vein Stenosis: The Role of Parenchymal Lung Disease and Pulmonary Vascular Disease
    Vyas-Read, Shilpa
    Varghese, Nidhy P.
    Suthar, Divya
    Backes, Carl
    Lakshminrusimha, Satyan
    Petit, Christopher J.
    Levy, Philip T.
    CHILDREN-BASEL, 2022, 9 (05):
  • [6] Using Omics to Understand and Treat Pulmonary Vascular Disease
    Hemnes, Anna R.
    FRONTIERS IN MEDICINE, 2018, 5
  • [7] Echocardiography in Pediatric Pulmonary Arterial Hypertension Early Study on Assessing Disease Severity and Predicting Outcome
    Ploegstra, Mark-Jan
    Roofthooft, Marcus T. R.
    Douwes, Johannes M.
    Bartelds, Beatrijs
    Elzenga, Nynke J.
    van de Weerd, Dick
    Hillege, Hans L.
    Berger, Rolf M. F.
    CIRCULATION-CARDIOVASCULAR IMAGING, 2015, 8 (01)
  • [8] Advanced pulmonary vascular disease: the Eisenmenger syndrome
    Kumar, R. Krishna
    Sandoval, Julio
    CARDIOLOGY IN THE YOUNG, 2009, 19 : 39 - 44
  • [9] Advanced pulmonary vascular disease: the Eisenmenger syndrome
    Kumar, R. Krishna
    Sandoval, Julio
    CARDIOLOGY IN THE YOUNG, 2009, 19 (06) : 622 - 626
  • [10] National Heart, Lung, and Blood Institute Workshop Improving Outcomes for Pulmonary Vascular Disease
    Robbins, Ivan M.
    Moore, Timothy M.
    Blaisdell, Carol J.
    Abman, Steven H.
    CIRCULATION, 2012, 125 (17) : 2165 - 2170